NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With RRMM
Updated: Jun 21, 2022
NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma
The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.
Sponsor
Collaborator
Glenmark Pharmaceuticals S.A.
ClinicalTrials.gov Identifier: NCT03309111
Official Title: A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma
First Posted : October 13, 2017
Click here to see details on ClinicalTrials.gov
Biological: ISB 1342
ISB 1342 (formerly known as GBR 1342)
Anti-CD38 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1342
Anti-CD38/Anti-CD3 Bispecific Monoclonal Antibody GBR 1342
Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342
BEAT GBR 1342
CD38xCD3 BsAb GBR 1342
GBR 1342
GBR-1342
GBR1342
Locations
United States, Maryland
United States, Minnesota
United States, New York
United States, North Carolina
United States, Tennessee
Europe
France